Clinical Trial Update: An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 dose-escalation/expansion study of INCB059872 in advanced malignancies, assessing safety and preliminary activity; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• INCB059872

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors and Hematologic Malignancy | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-12